Despite the availability of vaccines, COVID-19 continues to be aggressive, especially in immunocompromised individuals. Therefore, the development of a specific therapeutic agent with antiviral activity against SARS-CoV-2 is necessary. The infection pathway starts when the Receptor Binding Domain of the viral Spike protein interacts with the Angiotensin Converting Enzyme 2 (ACE2) receptor, which acts as a host receptor for the RBD expressed on the host cell surface. In this scenario, ACE2 analogs binding to RBD and preventing the cell entry can be promising antiviral agents. Most of the ACE2 residues involved in the interaction belong to the α1 helix, more specifically to the minimal fragment ACE2(24-42). In order to increase the stability of the secondary structure and thus antiviral activity, we designed different triazole-stapled analogs, changing the position and the number of bridges. The peptide called P3, which has the triazole-containing bridge in positions 36-40, showed promising antiviral activity at micromolar concentration, assessed by plaque reduction assay. On the other hand, the double-stapled peptide P4 lost the activity, showing that excessive rigidity disfavors the interaction with RBD.

Antiviral activity against SARS-CoV-2 of conformationally constrained helical peptides derived from angiotensin-converting enzyme-2 / Michael Quagliata, Maria Alfreda Stincarelli, Anna Maria Papini, Simone Giannecchini, Paolo Rovero. - In: ACS OMEGA. - ISSN 2470-1343. - ELETTRONICO. - 8:(2023), pp. 22665-22672. [10.1021/acsomega.3c01436]

Antiviral activity against SARS-CoV-2 of conformationally constrained helical peptides derived from angiotensin-converting enzyme-2.

Michael Quagliata;Maria Alfreda Stincarelli;Anna Maria Papini;Simone Giannecchini;Paolo Rovero
2023

Abstract

Despite the availability of vaccines, COVID-19 continues to be aggressive, especially in immunocompromised individuals. Therefore, the development of a specific therapeutic agent with antiviral activity against SARS-CoV-2 is necessary. The infection pathway starts when the Receptor Binding Domain of the viral Spike protein interacts with the Angiotensin Converting Enzyme 2 (ACE2) receptor, which acts as a host receptor for the RBD expressed on the host cell surface. In this scenario, ACE2 analogs binding to RBD and preventing the cell entry can be promising antiviral agents. Most of the ACE2 residues involved in the interaction belong to the α1 helix, more specifically to the minimal fragment ACE2(24-42). In order to increase the stability of the secondary structure and thus antiviral activity, we designed different triazole-stapled analogs, changing the position and the number of bridges. The peptide called P3, which has the triazole-containing bridge in positions 36-40, showed promising antiviral activity at micromolar concentration, assessed by plaque reduction assay. On the other hand, the double-stapled peptide P4 lost the activity, showing that excessive rigidity disfavors the interaction with RBD.
2023
8
22665
22672
Michael Quagliata, Maria Alfreda Stincarelli, Anna Maria Papini, Simone Giannecchini, Paolo Rovero
File in questo prodotto:
File Dimensione Formato  
Quagliata-ACS_Omega_2023.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 1.99 MB
Formato Adobe PDF
1.99 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1311400
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact